GrainCorp shares: FY26 earnings guidance forecasts lower profits

GrainCorp has issued lower FY26 earnings guidance as oversupply and weak global prices put pressure on margins.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The GrainCorp Ltd (ASX: GNC) share price is in focus today after the company released its FY26 earnings guidance, forecasting underlying EBITDA of $200–240 million and underlying NPAT between $20–50 million, both lower than FY25 results.

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face.

Image source: Getty Images

What did GrainCorp report?

  • FY26 underlying EBITDA guidance: $200–240 million (FY25: $308 million)
  • FY26 underlying NPAT guidance: $20–50 million (FY25: $87 million)
  • Export volumes expected: 5.5–6.5 million tonnes (FY25: 7.0mmt)
  • Receival volumes anticipated: 11.0–12.0 million tonnes (FY25: 13.3mmt)
  • Nutrition and Energy average crush margins steady with FY25
  • Agri energy contribution expected to be lower due to US biofuels uncertainty

What else do investors need to know?

GrainCorp highlighted that global grain markets are experiencing oversupply and low prices, leading to multi-year low export margins and weaker financial performance. Slow grower selling on the east coast and reduced incentives for grain delivery are adding to the pressure on margins and volumes.

In response, GrainCorp is accelerating cost management measures to ensure sustainability while maintaining reliable services for growers. The company described its balance sheet as strong and reaffirmed confidence in its ongoing strategic direction. Guidance remains subject to variables like grain volumes, export timing, and oilseed margins.

What did GrainCorp management say?

GrainCorp Managing Director and CEO, Robert Spurway, said:

Record global production has created an oversupply of grain, outpacing demand growth and placing downward pressure on commodity prices for the whole market. Despite strong ECA production volumes, with ABARES estimating a 2025-26 ECA winter crop of 31.2 million tonnes (mmt), the current abundance of global supply and low grain prices have reduced incentives for growers to deliver grain to market. As a result, GrainCorp is experiencing lower margins on grain handled in FY26.

What's next for GrainCorp?

Looking ahead, GrainCorp plans to keep managing costs closely and maintain high-quality service for Australian growers during this market downturn. The company's balance sheet remains robust, supporting its long-term strategy across the food, feed, and energy value chain.

Management will update investors on further market developments, including new season opportunities late in the year. The next key update will be at the AGM on 18 February 2026.

GrainCorp share price snapshot

Ove the past 12 months, GrainCorp shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on ASX Share Market News

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
ASX Share Market News

Record breaker! The ASX 200 just hit a fresh all-time high

Investors just sent the ASX 200 into uncharted territory.

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

An old-fashioned news boy stands on a stool and yells through a microphone in an open field.
ASX Share Market News

Why is everyone talking about Domino's, Light & Wonder and BHP shares on Wednesday?

BHP, Light & Wonder, and Domino’s shares are turning heads today. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »